Features Analysis of Major Players Appasamy Associates Private Limited, Carl Zeiss Meditec AG, DGH Technology Inc., Halma plc, Keeler USA, Lumibird Medical, Micro Medical Devices, NIDEK Co. Ltd., ...
The FDA reviews drug approval decisions that are expected in March 2025. The FDA is reviewing the application for bentracimab for use as a ticagrelor reversal agent in patients with uncontrolled ...
MyChesCo on MSN3h
Breakthrough Gene Therapy OCU410 Could Save Millions from Vision Loss – Phase 2 Milestone Achieved!Ocugen, Inc. (NASDAQ: OCGN) has announced the completion of dosing in the Phase 2 portion of its ArMaDa clinical trial for ...
Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...
As Valentine’s Day approaches, it turns out love really can be the best medicine - not just for your heart but for your overall well-being, according to health experts.
In this Healio Video Perspective from Hawaiian Eye 2025, I. Paul Singh, MD, discusses the AquaLumen, a subconjunctival bypass technology to lower IOP in patients with glaucoma.
Light adjustable lenses have strong visual and refractive outcomes in patients who have previously undergone radial keratotomy.
Standalone canaloplasty and trabeculotomy can deliver meaningfully reduced IOP in the long term and require fewer topical therapy agents.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback